Posted on 01/03/2010 in Pharmaceutical Company Product News Lundbeck has presented results from a clinical trial of the stroke treatment desmoteplase which it believes supports the drug's efficacy.
Post hoc analysis of evidence from the phase III study showed that patients with visible arterial occlusion or high-grade stenosis on baseline angiographies responded better to desmoteplase when compared to placebo.
It will be hoped that this data will assist the drug's application for approval by the Food and Drug Administration, which has granted the compound fast-track designation.
Anders Gersel Pedersen, executive vice-president and head of drug development at Lundbeck, stated that its treatment represents a solution to an unmet medical need.
He said: "Desmoteplase has the potential to treat patients ? up to nine hours after onset of symptoms.
"No treatment is available today that allows patients to reach hospital and be diagnosed within this extended time window."
Last month, the company confirmed Jacob Tolstrup as its new vice-president of investor relations and corporate communications, making him the youngest vice-president employed by Lundbeck.Other news stories from 01/03/2010
Read more in the Zenopa News Archive
How this news is generated
|
